GAMMA Investing LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 14.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,845 shares of the company’s stock after acquiring an additional 3,238 shares during the quarter. Eli Lilly and Company accounts for approximately 1.2% of GAMMA Investing LLC’s portfolio, making the stock its 12th largest holding. GAMMA Investing LLC’s holdings in Eli Lilly and Company were worth $31,000,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Grant Private Wealth Management Inc raised its holdings in shares of Eli Lilly and Company by 7.2% in the second quarter. Grant Private Wealth Management Inc now owns 1,261 shares of the company’s stock valued at $1,513,000 after purchasing an additional 85 shares during the last quarter. Avior Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 5.8% during the second quarter. Avior Wealth Management LLC now owns 6,424 shares of the company’s stock valued at $7,705,000 after purchasing an additional 354 shares in the last quarter. Crescent Sterling Ltd. boosted its holdings in Eli Lilly and Company by 3.8% during the second quarter. Crescent Sterling Ltd. now owns 384 shares of the company’s stock worth $461,000 after purchasing an additional 14 shares during the last quarter. Harbor Investment Advisory LLC boosted its holdings in Eli Lilly and Company by 2.8% during the second quarter. Harbor Investment Advisory LLC now owns 10,157 shares of the company’s stock worth $12,182,000 after purchasing an additional 278 shares during the last quarter. Finally, Canandaigua National Bank & Trust Co. bought a new stake in Eli Lilly and Company in the 2nd quarter worth about $9,009,000. Institutional investors own 82.53% of the company’s stock.
Key Eli Lilly and Company News
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: The FDA granted Breakthrough Therapy designation to Lilly’s investigational KRAS G12C inhibitor olomorasib for previously treated patients with advanced pancreatic cancer. The designation may accelerate development and regulatory interaction for a potential new oncology revenue stream. Lilly’s olomorasib receives FDA Breakthrough Therapy designation
- Positive Sentiment: Lilly is collaborating with Amplia Therapeutics to test olomorasib with narmafotinib in a Phase 1b/2b trial for advanced non-small cell lung cancer. The combination could expand olomorasib’s potential use beyond pancreatic and other cancers, although it remains an early-stage opportunity. Amplia collaboration with Lilly on olomorasib trial
- Positive Sentiment: Lilly will allow a limited number of patients to seek special access to experimental obesity drug retatrutide before potential FDA approval. The move highlights demand for the next-generation therapy and keeps attention on Lilly’s obesity pipeline. Lilly to offer early access to retatrutide
- Neutral Sentiment: Lilly’s upcoming earnings report is the immediate focus. Investors will look for continued prescription and revenue momentum from Mounjaro and Zepbound, management’s outlook, and updates on manufacturing capacity and pricing. Will Mounjaro and Zepbound drive Lilly’s Q2 results?
- Negative Sentiment: Investor expectations are elevated after Lilly’s powerful multiyear rally and roughly $1 trillion-plus valuation. Valuation analyses question whether projected cash flows justify the current price, increasing downside risk if earnings or guidance fall short. Eli Lilly stock looks below fair value on cash flow
- Negative Sentiment: Competition in the obesity-drug market remains a concern, as Novo Nordisk is attempting to regain ground. Any evidence of slowing demand, pricing pressure or improved rival products could challenge Lilly’s premium growth expectations. Obesity battle heats up between Novo and Lilly
Analysts Set New Price Targets
Read Our Latest Stock Analysis on Eli Lilly and Company
Eli Lilly and Company Stock Performance
Shares of LLY stock opened at $1,115.68 on Wednesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The firm has a market cap of $1.05 trillion, a price-to-earnings ratio of 39.63, a P/E/G ratio of 1.39 and a beta of 0.51. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,249.45. The firm’s 50-day simple moving average is $1,154.75 and its two-hundred day simple moving average is $1,044.52.
Eli Lilly and Company Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is 24.58%.
Eli Lilly and Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
